Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
List, A F, Bennett, J M, Sekeres, M A, Skikne, B, Fu, T, Shammo, J M, Nimer, S D, Knight, R D, Giagounidis, AVolume:
28
Language:
english
Journal:
Leukemia
DOI:
10.1038/leu.2013.305
Date:
May, 2014
File:
PDF, 440 KB
english, 2014